




# NeuroNEXT Network

## Standard Operating Procedure (SOP) Sharing Data with Industry Collaborators Version 2.0 SOP NN GA 109

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

<p><b>Signature and Date:</b></p> <p>DocuSigned by Christopher Coffey</p> <p>   I approve this document 14-Feb-2023   12:44:14 PM PST</p> <p>14-Feb-2023</p> <p>C68AC8DD80334CF982AED1200765F147</p>
<p><b>Name and Title:</b> Christopher S. Coffey, PhD (DCC Principal Investigator)</p>
<p><b>Signature and Date:</b></p> <p>DocuSigned by Merit Cudkowicz</p> <p>   I approve this document 13-Feb-2023   8:42:53 AM EST</p> <p>13-Feb-2023</p> <p>9F8FE4180E504C6AB0A67B835E80C644</p>
<p><b>Name and Title:</b> Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)</p>
<p><b>Signature and Date:</b></p> <p>DocuSigned by Marianne Chase</p> <p>   I approve this document 13-Feb-2023   8:45:56 AM EST</p> <p>13-Feb-2023</p> <p>58FE690F6BCA4F2390E3DA15BCE3F578</p>
<p><b>Name and Title:</b> Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)</p>

**Signature and Date:**

DocuSigned by DIXIE ECKLUND  
 | I approve this document  
13-Feb-2023 | 9:33:21 AM PST  
7006AF622EFC40B6A067A08EC02591B6

13-Feb-2023

**Name and Title:** Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

**Signature and Date:**

DocuSigned by Stacey Grabert  
 | I approve this document  
22-Feb-2023 | 11:34:23 AM EST  
60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

**Name and Title:** Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

**Signature and Date:**

DocuSigned by Joan Ohayon  
 | I approve this document  
13-Feb-2023 | 11:08:24 AM PST  
72C6AAFD8CC4485582ACA0700072901A

13-Feb-2023

**Name and Title:** Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

## NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SHARING DATA WITH INDUSTRY COLLABORATORS

### 1. POLICY

The purpose of this SOP is to describe NeuroNEXT Data Coordinating Center (DCC) and Clinical Coordinating Center (CCC) roles, responsibilities, policies, and procedures associated with sharing study data with industry Collaborators under terms of a Cooperative Research & Development Agreement (CRADA). Additional data sharing processes and procedures for NeuroNEXT Network studies are described in SOP NN GA 107 *Data Sharing*.

#### ***Sharing Data with Protocol Principal Investigators***

The Protocol PI will receive a copy of the final, un-blinded results, tables, and datasets from the DCC within sixty (60) days after conclusion of the study, or according to the provisions set forth in the executed CRADA for the study. The Protocol PI may receive his or her site-specific data from the DCC at any time during or after the study.

The DCC will perform ongoing and final statistical analyses for NeuroNEXT and will collaborate with the PPI to generate manuscripts and abstracts as well as the primary manuscript that describes the final study results. The Collaborator may perform its own statistical analysis of the final, un-blinded study data, either with in-house or contract statisticians.

All publications resulting from NeuroNEXT clinical trials will be reviewed by the NeuroNEXT Publication and Data Sharing Committees according to NN SOP GA 106 Publication Policy.

#### ***Sharing Data with Clinical Study Site Principal Investigators***

As described in the Notice of Grant Award, each CSS will generally be considered to own the data that have been generated at its respective site during the study. All study data must be transmitted to the DCC. A CSS may receive its site-specific data from the DCC at any time during or after the study but will not receive subject-level data from other CSS. Except for the Protocol PI's CSS, no CSS will receive the final, un-blinded results until at least three (3) years after conclusion of the study, or according to the provisions set forth in the executed CRADA for the study.

#### ***Sharing Data with the Scientific Community***

Individuals or groups who are not participants in the NeuroNEXT CRADA study will not be given access to any study-related data from the DCC or CSS. They may access only de-identified datasets and associated documentation archived for public access.

#### ***Sharing De-Identified Data Sets for Public Use***

The DCC will submit de-identified data sets and associated documentation to NINDS for archiving and public access at the request and direction of NINDS and as consistent with the current NINDS Data Management and Sharing Policy. The DCC will provide documentation with each final data set to ensure that other users can efficiently and accurately use the data set, and to prevent misinterpretation or misuse. This documentation may include information about how the data were collected, provide details about the code used to generate the dataset, and define variables and variable field locations.

To protect the rights and privacy of human subjects who participate in NeuroNEXT trials, study data will be redacted prior to sharing for public use to remove any personally identifying information. Any direct identifiers (e.g., name, contact information, Social Security Numbers) that may be present in study data will be removed prior to creation of the dataset. Indirect identifiers that could lead to deductive disclosure of participant identities (e.g., birth date) will be removed or otherwise de-identified.

### 2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E (R2). The policies and procedures described in this SOP apply to the NeuroNEXT CCC and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT researchers, staff, subcontractors, or other entities

associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

### 3. ROLES AND RESPONSIBILITIES

The DCC serves as the primary Statistical Analysis group for the NeuroNEXT Network, and performs ongoing and interim statistical analyses for all NeuroNEXT protocols. For most NeuroNEXT protocols, the DCC performs the ongoing statistical analyses and the primary statistical analysis of the final study data, and assists with secondary analyses as appropriate. The DCC also collaborates with Protocol and CSS Principal Investigators to generate manuscripts that describe study design and final study results.

The NeuroNEXT DCC is responsible for developing and validating database systems, collecting and storing data, and sharing study data according to the procedures described in this and other applicable NeuroNEXT Network SOPs.

### 4. APPLICABLE POLICIES AND GUIDELINES

NIH	Final NIH Statement on Sharing Research Data, February 26, 2003. <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html">http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html</a>
NIH	NIH Data Sharing Policy and Implementation Guidance March 5, 2003. <a href="http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm">http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm</a>
NIH	NIH Scientific Data Sharing: New Policy effective January 25, 2023 <a href="https://sharing.nih.gov/">https://sharing.nih.gov/</a>
NINDS	NINDS Archived Clinical Research Datasets <a href="https://www.ninds.nih.gov/current-research/research-funded-ninds/clinical-research/archived-clinical-research-datasets">https://www.ninds.nih.gov/current-research/research-funded-ninds/clinical-research/archived-clinical-research-datasets</a>

### 5. REFERENCES TO OTHER APPLICABLE SOPS

NN GA 106	Publication Policy Development
NN GA 107	Data Sharing
NN CS 704	System Security Measures and Website Access
NN CS 706	Retention and Protection of Electronic Records
NN BIO 901	Working with an External Biostatistician
NN BIO 902	Statistical Analysis Plan Development
NN BIO 904	Generation and Validation of Analysis Data Sets
NN BIO 906	Presenting Statistical Results for a Final Study Report

### 6. ATTACHMENTS

NN GA 109 – A	Document History
---------------	------------------

### 7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

DCC	Data Coordinating Center at The University of Iowa
CCC	Clinical Coordinating Center at Massachusetts General Hospital
Clinical Study Site (CSS)	Clinical site that conducts research for a NeuroNEXT protocol
Protocol Principal Investigator (PPI)	Principal Investigator of a NeuroNEXT protocol
Clinical Study Site Principal Investigator	Investigator who is responsible for the implementation and conduct of a specific NeuroNEXT protocol at a Clinical Study Site
DCC Biostatistician	Any Biostatistician who is a member of the DCC Biostatistics team
Lead Biostatistician	DCC Biostatistician who has primary statistical oversight for a NeuroNEXT protocol

Study Biostatistician

DCC Biostatistician assigned to a NeuroNEXT protocol. At least one Study Biostatistician will be assigned to each protocol, but only one Biostatistician will be assigned to prepare the randomization.

External Biostatistician

A Biostatistician who is not a member of the DCC Biostatistics Team. The External Biostatistician may be employed directly by a NeuroNEXT site, or engaged as a subcontractor.

## 8. SPECIFIC PROCEDURES

### A. Sharing Data with Protocol Principal Investigators

#	Who	Task	Attachment	Related SOP
1.	DCC Biostatisticians	During the course of the study, perform requested analyses and communicate the results to the PPI in the form of tables or data sets.		NN BIO 902 NN BIO 904
2.	DCC Biostatisticians	Provide a copy of the final, un-blinded results, tables, and data sets to the PPI and Industry Collaborator within sixty (60) days after conclusion of the study, or according to the provisions set forth in the executed CRADA for the study. The Protocol PI may receive his or her site-specific data from the DCC at any time during or after the study.		
3.	DCC Biostatisticians and PPI	For most studies, DCC Biostatisticians will: <ul style="list-style-type: none"> <li>perform the primary statistical analysis of the final study data;</li> <li>communicate the results to the PPI in the form of tables or data sets; and</li> <li>collaborate with the PPI to generate the primary manuscript that describes the final study results for review by the NeuroNEXT Publication and Data Sharing Committees.</li> </ul>		NN GA 106 NN BIO 906
4.	DCC Biostatisticians, PPI, External Biostatistician	If applicable to the protocol, and approved by NINDS, the PPI may engage a Biostatistician who is external to the DCC to perform the primary statistical analysis. In this case, the DCC will: <ul style="list-style-type: none"> <li>transmit the final data set to the external Biostatistician in an agreed-upon format using a secure, encrypted method; and</li> <li>offer to collaborate during the analysis phase; and</li> <li>collaborate with the external Biostatistician to generate the primary manuscript that describes the final study results for review by the NeuroNEXT Publication and Data Sharing Committee.</li> </ul>		NN GA 106 NN BIO 901 NN BIO 906

### B. Sharing Data with Clinical Study Site Principal Investigators

#	Who	Task	Attachment	Related SOP
1.	CSS	A CSS may submit written requests for transfers of their own site-specific data from the DCC during or after a study, but they will not receive subject-level data from other CSS.		

#	Who	Task	Attachment	Related SOP
2.	DCC	Transfer site-specific data only to the requesting CSS upon written request.		
3.	DCC Biostatisticians	Except for the Protocol PI's CSS, the final, un-blinded results will not be shared with other CSS until at least three (3) years after conclusion of the study, or according to the provisions set forth in the executed CRADA for the study.		

### C. Sharing De-Identified Data Sets for Public Use

#	Who	Task	Attachment	Related SOP
1.	DCC	<p>Redact data sets to remove all personally identifying information prior to sharing for public use.</p> <ul style="list-style-type: none"> <li>• Prior to creating the data set, remove all direct identifiers (e.g. name, contact information, SSN) that may be present in study data.</li> <li>• Remove or otherwise de-identify any indirect identifiers (e.g. birth date, procedure dates) that could lead to a deductive disclosure of participant identity.</li> </ul>		
2.	DCC	At the request and direction of NINDS, submit de-identified data sets and associated documentation to NINDS for archiving and public access, consistent with the current NINDS Data Management and Sharing Policy.		
3.	DCC Biostatisticians	<p>Provide documentation with each final data set. Documentation may include, but is not limited to, the following information:</p> <ul style="list-style-type: none"> <li>• how the data were collected;</li> <li>• details of the code used to generate the data set;</li> <li>• definitions of variables and variable field locations</li> </ul>		

Certificate Of Completion

Envelope Id: 6FEE2CB41BBF47B68E63F6020AB302FB

Status: Completed

Subject: Complete with DocuSign: NN GA 109 Sharing Data with Industry Collaborators v2.0.docx

Source Envelope:

Document Pages: 6

Signatures: 6

Envelope Originator:

Certificate Pages: 6

Initials: 0

Tania Leeder

AutoNav: Enabled

TLEEDER@PARTNERS.ORG

Envelopeld Stamping: Disabled

IP Address: 73.159.130.82

Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original

Holder: Tania Leeder

Location: DocuSign

2/13/2023 8:23:29 AM

TLEEDER@PARTNERS.ORG

Signer Events

Signature

Timestamp

Christopher Coffey

christopher-coffey@uiowa.edu

Security Level: Email, Account Authentication (Required), Login with SSO

Christopher Coffey

Sent: 2/13/2023 8:25:32 AM

Viewed: 2/14/2023 3:44:03 PM

Signed: 2/14/2023 3:44:17 PM

Signature Adoption: Pre-selected Style

Signature ID:

C68AC8DD-8033-4CF9-82AE-D1200765F147

Using IP Address: 128.255.113.139

With Signing Authentication via DocuSign password

With Signing Reasons (on each tab):

I approve this document

Electronic Record and Signature Disclosure:

Accepted: 2/14/2023 3:44:03 PM

ID: 230a1efa-6563-4c74-8f67-902a65520779

DIXIE ECKLUND

dixie-ecklund@uiowa.edu

Security Level: Email, Account Authentication (Required), Login with SSO

DocuSigned by DIXIE ECKLUND

Dixie Ecklund

I approve this document  
13-Feb-2023 | 9:33:21 AM PST

7006AF622EFC40B6A067A08EC02591B6

Sent: 2/13/2023 8:25:32 AM

Viewed: 2/13/2023 12:28:10 PM

Signed: 2/13/2023 12:33:26 PM

Signature Adoption: Drawn on Device

Signature ID:

7006AF62-2EFC-40B6-A067-A08EC02591B6

Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password

With Signing Reasons (on each tab):

I approve this document

Electronic Record and Signature Disclosure:

Accepted: 2/13/2023 12:28:10 PM

ID: 1b7c4fab-8201-4b35-9dfb-a2961045debc

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Joan Ohayon  
ohayonj@ninds.nih.gov  
Security Level: Email, Account Authentication (Required)

*Joan Ohayon*

Sent: 2/13/2023 8:25:34 AM  
Viewed: 2/13/2023 2:07:45 PM  
Signed: 2/13/2023 2:08:28 PM

Signature Adoption: Pre-selected Style  
Signature ID:  
72C6AAFD-8CC4-4855-82AC-A0700072901A  
Using IP Address: 71.178.185.120

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Accepted: 2/13/2023 2:03:22 PM  
ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase  
MCHASE@mgh.harvard.edu  
Sr Director, Clinical Trial Operations  
Insight OBO The Massachusetts General Hospital  
Security Level: Email, Account Authentication (Required)

*Marianne Chase*


Sent: 2/13/2023 8:25:32 AM  
Viewed: 2/13/2023 8:45:31 AM  
Signed: 2/13/2023 8:45:59 AM

Signature Adoption: Pre-selected Style  
Signature ID:  
58FE690F-6BCA-4F23-90E3-DA15BCE3F578  
Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Not Offered via DocuSign

Merit Cudkowicz  
cudkowicz.merit@mgh.harvard.edu  
Chief of Neurology  
Security Level: Email, Account Authentication (Required), Logged in

DocuSigned by Merit Cudkowicz  
  
I approve this document  
13-Feb-2023 | 8:42:53 AM EST  
9F8FE4180E504C6AB0A67B835E80C644


Sent: 2/13/2023 8:25:33 AM  
Viewed: 2/13/2023 8:42:42 AM  
Signed: 2/13/2023 8:42:55 AM

Signature Adoption: Pre-selected Style  
Signature ID:  
9F8FE418-0E50-4C6A-B0A6-7B835E80C644  
Using IP Address: 68.239.56.73

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Accepted: 2/13/2023 8:42:42 AM  
ID: f2611608-0357-4d99-92a9-7b540ea3ac43



Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	  Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49  With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/13/2023 8:25:33 AM Viewed: 2/22/2023 11:34:12 AM Signed: 2/22/2023 11:34:26 AM
<b>Electronic Record and Signature Disclosure:</b> Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/13/2023 8:25:34 AM
Certified Delivered	Security Checked	2/22/2023 11:34:12 AM
Signing Complete	Security Checked	2/22/2023 11:34:26 AM
Completed	Security Checked	2/22/2023 11:34:26 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact Insight OBO The Massachusetts General Hospital:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu)

### **To advise Insight OBO The Massachusetts General Hospital of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

### **To request paper copies from Insight OBO The Massachusetts General Hospital**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

### **To withdraw your consent with Insight OBO The Massachusetts General Hospital**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.